Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

439
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
439
Tumor Immunotherapy01:27

Tumor Immunotherapy

526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

68.3K
Overview
68.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Vasculitis-Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Fibroblast Yap/Taz Signaling in Extracellular Matrix Homeostasis and Tissue Fibrosis.

Journal of clinical medicine·2024
Same author

Advances and challenges in management of large vessel vasculitis.

Rheumatology and immunology research·2023
Same author

mRNA vaccine against fibroblast activation protein ameliorates murine models of inflammatory arthritis.

Rheumatology and immunology research·2023
Same author

Schnitzler syndrome-An underdiagnosed adult-onset autoinflammatory disease.

International journal of rheumatic diseases·2023
Same author

The bacterial link with rheumatoid arthritis.

International journal of rheumatic diseases·2023

Related Experiment Video

Updated: Jul 4, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Complement-targeted therapy for autoimmune diseases.

Cong-Qiu Chu1,2

  • 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.

Medical Review (2021)
|January 29, 2024
PubMed
Summary

Targeted therapies are advancing for autoimmune diseases by inhibiting complement activity. Small interfering RNA (siRNA) shows promise, potentially combined with autoantibody reduction for effective treatment.

Keywords:
autoimmune diseasescomplementdual targetsiRNA

More Related Videos

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

7.9K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

Related Experiment Videos

Last Updated: Jul 4, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

7.9K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

Area of Science:

  • Immunology
  • Pharmacology
  • Therapeutics

Background:

  • Complement-mediated hemolysis treatments show success, driving development of targeted therapies.
  • Therapies are expanding from rare autoimmune diseases to more common conditions.
  • Various drug classes (small molecules, peptides, monoclonal antibodies, siRNA) target complement activity.

Purpose of the Study:

  • To explore the development of targeted therapies for autoimmune diseases.
  • To evaluate the potential of small interfering RNA (siRNA) as a therapeutic tool.
  • To investigate combination strategies for complex autoimmune conditions.

Main Methods:

  • Review of current drug development for complement-targeted therapies.
  • Analysis of small interfering RNA (siRNA) mechanisms in suppressing complement production.
  • Exploration of dual-modality treatment approaches.

Main Results:

  • Targeted therapies for complement-mediated conditions are successful and safe.
  • siRNA is emerging as a potent therapeutic agent for suppressing complement.
  • Combination therapy (siRNA plus autoantibody reduction) is clinically feasible.

Conclusions:

  • Targeted therapies are expanding for autoimmune diseases, leveraging complement inhibition.
  • siRNA offers a promising approach to suppress complement production.
  • Combined siRNA and autoantibody reduction strategies may significantly impact autoimmune disease management.